Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine. [Corrigendum]
Nanda K, Moss AC.Clinical Pharmacology: Advances and Applications. 2012, 4:41–50.The authors apologize for errors on Tables 1, 2, and 3.Table1Citation 40, Hussain et al, should have been citation 44, Shire US Inc.Table 2Lichtenstein et al data, the confidence interval (CI) of the odds...
Enregistré dans:
Auteurs principaux: | Nanda K, Moss AC |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/03009643a99b4fe0be7bb0f9e8f3d55c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine
par: Nanda K, et autres
Publié: (2012) -
Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
par: Maconi G, et autres
Publié: (2021) -
Identification of Pharmacological Autophagy Regulators of Active Ulcerative Colitis
par: Peishan Qiu, et autres
Publié: (2021) -
Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers
par: Jakate A, et autres
Publié: (2019) -
Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven®)
par: Bartosh NS, et autres
Publié: (2013)